BICX - BioCorRx gets FDA clearance for BICX104 Opioid Use Disorder treatment trials

BioCorRx (BICX) announces that the U.S. FDA has given the company clearance to proceed to human trials for BICX104, an implantable naltrexone pellet for the treatment of Opioid Use Disorder ((OUD)).BICX104 is a biodegradable, long-acting subcutaneous pellet of naltrexone being developed in partnership with the National Institutes of Health ((NIH)) and the National Institute on Drug Abuse.The first-in-human clinical trial for BICX104 is expected to commence later this year, which will assess longevity, safety and tolerability of the treatment.

For further details see:

BioCorRx gets FDA clearance for BICX104 Opioid Use Disorder treatment trials